In Brief: OncorMed
This article was originally published in The Gray Sheet
Executive Summary
OncorMed: Obtains license for BRCA1 genetic markers for breast and ovarian cancer from the Regents of the University of California, Berkeley. In July, the university's application for the genetic markers was allowed by the U.S. Patent Office becoming the first BRCA1 patent to achieve this status, according to OncorMed. The Gaithersburg, Maryland firm currently offers genetic testing services for both BRCA1 and BRCA2 genes for susceptibility to breast and ovarian cancer...